In February of 2020, the FDA issued an opinion to encourage cannabis product development through botanical drug guidance:
Cannabis study drugs containing hemp (under 0.3% THC on a dry weight basis) will utilize a 5-step approach
Cannabis study drugs controlled under Schedule I of the CSA (greater than 0.3%THC on a dry weight basis) will utilize a 7-step approach